Skip to Content

Teduglutide Disease Interactions

There are 6 disease interactions with teduglutide:

Moderate

Teduglutide (applies to teduglutide) biliary and pancreatic disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cholelithiasis, Pancreatitis

Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical studies with teduglutide. For identification of the onset or worsening of gallbladder/biliary/pancreatic disease, patients should undergo laboratory assessment of bilirubin, alkaline phosphatase, lipase and amylase within 6 months prior to starting teduglutide, and at least every 6 months while on treatment; or more frequently if needed. If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder, biliary tract and/or pancreas is recommended; and the need for continued teduglutide treatment should be reassessed.

Moderate

Teduglutide (applies to teduglutide) congestive heart failure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Fluid Retention

Fluid overload and congestive heart failure have been observed in clinical trials with teduglutide. This was probably related to enhanced fluid absorption associated with the medication. If fluid overload occurs, parenteral support should be adjusted and treatment should be reassessed, especially in patients with underlying cardiovascular disease. If significant cardiac deterioration develops while on teduglutide, the need to continue treatment should be reassessed.

Moderate

Teduglutide (applies to teduglutide) intestinal obstruction

Moderate Potential Hazard, Moderate plausibility.

Intestinal obstruction has been reported in clinical trials with teduglutide. In patients who develop intestinal or stomal obstruction, treatment with teduglutide should be temporarily discontinued while the patient is clinically managed. Treatment may be restarted when the obstructive episode resolves, if clinically indicated. Caution is advised in patients with risk factors for intestinal obstruction.

Moderate

Teduglutide (applies to teduglutide) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Teduglutide pharmacokinetics has not been assessed in patients with severe hepatic impairment. Caution and monitoring is advised. Patients with moderate hepatic impairment showed lower Cmax and AUC when compared to healthy matched control subjects after a single subcutaneous dose of teduglutide. However, no dose adjustment is necessary for patients with mild and moderate liver impairment.

Moderate

Teduglutide (applies to teduglutide) neoplasias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Skin Cancer, Neoplasia -- Estrogen Dependent, Lung Cancer, Prostate Tumor, Biliary Tract and Hepatic Tumor, Urinary Tumor

Based on the pharmacologic activity and findings in animals, teduglutide has the potential to cause hyperplastic changes including neoplasia. In patients at increased risk for malignancy, the clinical decision to use teduglutide should be considered only if the benefits outweigh the risks. In patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic), therapy should be discontinued. Patients with colorectal polyps, should have these removed within 6 months prior to starting treatment with teduglutide. In patients with active non- gastrointestinal malignancy, the clinical decision to continue therapy should be made based on risk- benefit considerations.

Moderate

Teduglutide (applies to teduglutide) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Teduglutide is primarily cleared by the kidney and caution is advised when using in patients with moderate to severe renal impairment. The manufacturers recommend to reduced the dose by 50% in patients with moderate and severe renal impairment (creatinine clearance less than 50 mL/min), and end-stage renal disease.

Teduglutide drug interactions

There are 16 drug interactions with teduglutide

Teduglutide alcohol/food interactions

There is 1 alcohol/food interaction with teduglutide

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.